Mesoblast Limited (MESO) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Mesoblast Limited (MESO): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why MESO has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with MESO. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. Screeners that show a trailing twelve-month revenue near $65 million are running on the period through December 31, 2025 and understate the current run rate, which puts the multiple closer to 17 times sales than 30 times. The audited fiscal 2026 annual report on Form 20-F had not been filed as of mid-August 2026, so the full-year figures above come from the July 2026 quarterly activity statement.
What could move MESO from here
In short: the drivers cited most often are Ryoncil's first full year of sales, Label extension into adult graft versus host disease, Rexlemestrocel-L reaching regulatory and trial milestones. The risk cited most often against it is nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the MESO is it a buy page. This page deliberately stops at the numbers.
Investing in Mesoblast Limited with AI
Connect the broker you already use and ask Walnut's AI how MESO fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Mesoblast Limited (MESO)?
+
There is no meaningful consensus price target for MESO, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does MESO have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move MESO?
+
The drivers and the risks are laid out on this page and in more depth on the MESO "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a August 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.